Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (CANF) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CANF · as of Sep 30, 2025
Ownership Breakdown
15
Institutional Holders
$952,611
Total Inst. Value
▲ $2,489 vs Q2
853,645
Shares Outstanding
freeFloat 95.09%
1.54M
13F Shares Held
▲ 633,597 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CANF largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SABBY MANAGEMENT, LLC pharmaceutical preparations | 1.41M | 8.53% | 8.53% | $870.63M | Nov 14, 2025 | ▲ 626.3K |
RHUMBLINE ADVISERS pharmaceutical preparations | 57.9K | 35.16% | 35.16% | $35.85M | Nov 6, 2025 | ▲ 350 |
MORGAN STANLEY pharmaceutical preparations | 12.6K | 11.03% | 11.03% | $7.77M | May 27, 2026 | ▲ 2.6K |
BNP PARIBAS ARBITRAGE, SNC pharmaceutical preparations | 16.6K | 10.06% | 10.06% | $10.27M | Nov 13, 2025 | ▼ 1.0K |
BOGART WEALTH, LLC pharmaceutical preparations | 15.0K | 9.13% | 9.13% | $9.32M | Oct 27, 2025 | NEW |
CAPTRUST FINANCIAL ADVISORS pharmaceutical preparations | 11.4K | 6.90% | 6.90% | $7.04M | Nov 19, 2025 | — held |
TWO SIGMA SECURITIES, LLC pharmaceutical preparations | 10.6K | 6.46% | 6.46% | $6.59M | Nov 14, 2025 | ▼ 5.4K |
FIFTH THIRD BANCORP pharmaceutical preparations | 3.0K | 1.82% | 1.82% | $1.86M | Nov 7, 2025 | — held |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 2.7K | 1.64% | 1.64% | $1.67M | Nov 13, 2025 | — held |
UBS GROUP AG pharmaceutical preparations | 1.3K | 0.79% | 0.79% | $810,000 | Nov 13, 2025 | ▼ 4.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
3
Increased
+629.3K shares2
New Positions
first time holders3
Decreased
−10.6K shares2
Sold Out
fully exitedNet shares change (top 50)
+618.7K
+629.3K / −10.6K
Net new holders
+0
2 new / 2 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CANF insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Farbstein Motti CEO, CFO and COO | Jun 4, 2026 | Award | 24,000 | $2.04 | $49.0K | 33.1K | Form 4 ↗ |
Fishman Pnina Chief Scientific Officer | Jun 4, 2026 | Award | 24,000 | $2.04 | $49.0K | 34.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Can-Fite BioPharma Ltd. (CANF) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 4.91%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Can-Fite BioPharma Ltd. is SABBY MANAGEMENT, LLC, holding approximately 1.41 million shares — equal to 8.53% of outstanding shares — as of September 30, 2025.
A total of 15 institutional investors currently hold CANF stock, with a combined institutional value of approximately $952,611 as of the most recent 13F filing period.
Frequently asked questions
CANF ownershipCan-Fite BioPharma Ltd. (CANF) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is SABBY MANAGEMENT, LLC with a 8.53% stake. Company insiders hold 4.91%. Data sourced from SEC Form 13F as of September 30, 2025.